证券代码：603229 证券简称：奥翔药业 公告编号：2026-007 浙江奥翔药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江奥翔药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的磷酸芦可替尼原料药的《化学原料药上市申请批准通知书》。 现就相关情况公告如下： 一、药品的基本情况 化学原料药名称：磷酸芦可替尼 登记号：Y20240001130 包装规格：1.0kg/桶，2.0kg/桶，5.0kg/桶，10.0kg/桶 申请事项：境内生产化学原料药上市申请 生产企业：浙江奥翔药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品的相关信息 磷酸芦可替尼是一种 Janus 激酶（JAK）JAK1/2 选择性抑制剂，适用于治疗 中危或高危的原发性骨髓纤维化、真性红细胞增多症继发的骨髓纤维化、原发性 血小板增多症继发的骨髓纤维化成年患者的脾肿大及相关症状，也可用于治疗糖 ...

一、药品的基本情况 药品名称：恩替卡韦片 剂型：片剂 证券代码：603229 证券简称：奥翔药业 公告编号：2026-006 浙江奥翔药业股份有限公司 关于全资子公司获得恩替卡韦片《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江奥翔药业股份有限公司（以下简称"公司"）全资子公司浙江麒 正药业有限公司（以下简称"麒正药业"）收到国家药品监督管理局核准签发的 恩替卡韦片《药品注册证书》（证书编号：2026S00779）。现就相关情况公告如下： 处方药/非处方药：处方药 药品批准文号：国药准字 H20263653 上市许可持有人：浙江麒正药业有限公司 生产企业：浙江麒正药业有限公司 规格：0.5mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品的相关信 ...

Group 1 - The company acknowledges that stock price fluctuations in the secondary market are influenced by various factors and encourages investors to make rational decisions and be aware of investment risks [2] - The company aims to focus on its core business, continuously improve its operations, and accelerate product sales deployment [2] - The company is committed to ongoing research and development of new technologies and products to explore new performance growth points for sustainable, healthy, and stable development [2]

Core Viewpoint - Aoxiang Pharmaceutical announced the repayment of idle funds raised from a non-public stock issuance for temporary liquidity support, amounting to 10 million RMB by February 25, 2026 [1] Group 1 - The company has cumulatively repaid 10 million RMB of the idle funds from the 2022 non-public stock issuance [1]

一、募集资金临时补充流动资金情况 浙江奥翔药业股份有限公司（以下简称"公司"）于2025年4月28日召开第 四届董事会第七次会议、第四届监事会第六次会议，审议通过了《关于使用部分 闲置募集资金暂时补充流动资金的议案》，同意公司及全资子公司浙江麒正药业 有限公司（以下简称"麒正药业"）使用不超过人民币15,000万元的闲置募集资 金暂时补充流动资金，使用期限自公司董事会审议通过之日起12个月内。具体内 容见公司于2025年4月30日披露的《浙江奥翔药业股份有限公司关于使用部分闲 置募集资金暂时补充流动资金的公告》（公告编号：2025-020）。 | 发行名称 | 2022年度非公开发行股票 | | --- | --- | | 募集资金到账时间 | 2023年1月18日 | | 临时补流募集资金金额（万元） | 15,000.00 | | 补流期限 | 2025-04-28至2026-04-27 | 二、归还募集资金的相关情况 证券代码：603229 证券简称：奥翔药业 公告编号：2026-005 浙江奥翔药业股份有限公司 关于提前归还部分用于临时补充流动资金的 募集资金的公告 本公司董事会及全体董事保证本公告内 ...

Group 1 - The core point of the article is that Aoxiang Pharmaceutical has made significant progress in expanding its market in Europe with the approval of its partner STADA Arzneimittel AG's subsidiary for the marketing of tofacitinib citrate tablets, projected to generate global sales of $1.168 billion in 2024 [1] - The company has invested approximately 6.96 million yuan in research and development, indicating a commitment to innovation and product development [1] - Aoxiang Pharmaceutical has been re-certified as a high-tech enterprise, which will allow it to benefit from tax incentives and other policy support for three years [1] Group 2 - In the past week (February 5 to 11, 2026), Aoxiang Pharmaceutical's stock price remained stable with a fluctuation range of 0.51%, reaching a high of 9.99 yuan and a low of 9.80 yuan on February 6 [2] - As of the market close on February 11, the stock price was 9.87 yuan, with a net outflow of 2.4335 million yuan in main capital and a turnover rate of 0.46% [2] - Technical indicators show that the stock price is between the 20-day resistance level of 10.27 yuan and the support level of 9.59 yuan, with the MACD indicator showing weakness [2] Group 3 - The company's Q3 2025 financial report indicates a revenue of 646 million yuan for the first three quarters, a year-on-year decrease of 6.40%, and a net profit attributable to shareholders of 207 million yuan, down 9.59% year-on-year [3] - In Q3 alone, the revenue was 164 million yuan, reflecting a year-on-year decline of 17.01%, with a net profit of 37.6858 million yuan, down 23.33% year-on-year [3] - The decline in revenue and profit is primarily attributed to intensified competition in cardiovascular products and increased R&D expenses, with a Q3 R&D expense ratio of 15.41% [3]

Core Viewpoint - The company, Aoxiang Pharmaceutical, has received a new High-tech Enterprise Certificate, indicating its recognition as a high-tech enterprise by relevant authorities in Zhejiang Province, which is crucial for its ongoing operations and potential funding opportunities [1] Group 1 - Aoxiang Pharmaceutical announced the receipt of the High-tech Enterprise Certificate from the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1] - The certificate was issued on December 19, 2025, and is valid for three years [1] - This recognition is a renewal of the company's previous certificate, which had expired [1]

本次高新技术企业的认定系公司原证书有效期满后的重新认定。根据《中华 人民共和国企业所得税法》以及国家对高新技术企业的相关税收规定，公司自本 次通过高新技术企业认定后连续三年（即 2025 年至 2027 年）可继续享受高新技 术企业的相关税收优惠政策，按 15%的所得税率缴纳企业所得税。 浙江奥翔药业股份有限公司 关于公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司（以下简称"公司"）于近日收到由浙江省经济 和信息化厅、浙江省财政厅、国家税务总局浙江省税务局联合颁发的《高新技术 企业证书》(证书编号:GR202533008051)，发证时间为 2025 年 12 月 19 日，有效 期三年。 证券代码：603229 证券简称：奥翔药业 公告编号：2026-004 公司 2025 年度已根据相关规定按 15%的税率计缴了企业所得税，本次通过 高新技术企业重新认定不影响公司 2025 年度的相关财务数据。 特此公告。 浙江奥翔药业股份有限公司董事会 2026 年 2 月 ...

Core Viewpoint - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has announced that its partner STADA Arzneimittel AG's subsidiary Spirig HealthCare AG has received approval from the Swiss Medicines Agency for the marketing of tofacitinib citrate tablets, marking a significant milestone for the company's international expansion efforts [1][4]. Group 1: Product Information - The product, tofacitinib citrate, is the world's first approved oral Janus kinase inhibitor, used for treating autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2]. - The commercial name for tofacitinib citrate is Xeljanz, developed by Pfizer, which received FDA approval in November 2012 and entered the Chinese market in March 2017. The global sales forecast for 2024 is approximately $1.168 billion [2]. Group 2: Company Impact - The approval for tofacitinib citrate tablets in Switzerland establishes a solid foundation for the company's business expansion in the Swiss market and is expected to positively influence its ongoing expansion into the European market, enhancing brand recognition and market share [4]. - The collaboration with STADA on this formulation product signifies a breakthrough in the company's integrated strategy of "intermediates + specialty APIs + formulations," enriching its product line and enhancing competitive advantages [4].

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]